You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大和上調信達生物(01801.HK)目標價至58元 評級「買入」
阿思達克 10-27 10:49
大和發表報告,對市場日益重視的降糖藥GLP-1進行檢視,並引述醫療行業報告指,內地糖尿病及肥胖病流行,估計2023年肥胖相關醫療開支將達4,000億元人民幣,佔內地總醫療開支22%。GLP-1在糖尿病範疇取得成功後,開始成為治療肥胖的重要藥物。 在相關股份中,該行首選為信達生物(01801.HK),預期公司旗下mazdutide將會成為首隻本土GLP-1減肥藥,有望取得病人市場佔有率15%,估計2031年該藥物銷售額52億元人民幣,對該股評級「買入」,目標價由50元上調至58元。主要風險包括藥物價格及滲透率不確定,以及下一代GLP-1藥物的安全度。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account